Impella 5.5保护下高风险心脏手术安全可行:IPCS试验结果
Impella-Protected Cardiac Surgery Trial是一项前瞻性、多中心、单臂研究,评估在严重左心室功能不全患者中,于脱离体外循环前启动经瓣膜左心室卸载的安全性和可行性。
要点
- 严重左心室功能不全患者术前启动Impella 5.5卸载可行。
- 术后心脏切开后心力衰竭发生率6%,主要安全终点事件12%。
- 30天和90天死亡率分别为2%和4%。
核心结论
- Impella 5.5保护下心脏手术在严重左心室功能不全患者中安全可行,是有前景的设备支持策略。
研究设计与样本
- 入选标准为左心室射血分数降低且计划择期或紧急常规心脏手术,排除术前使用正性肌力药或机械循环支持者。
- 主要疗效终点为至出院时心脏切开后心力衰竭,主要安全终点为术后90天内全因死亡、卒中和新需肾脏替代治疗的复合终点。
主要发现
- 基线左心室射血分数为25%(IQR 21.6–28.9),STS预测死亡风险为4.1%(IQR 2.5–7.1)。
- 索引心脏手术主要为单纯冠状动脉旁路移植术(56%)或冠状动脉旁路移植术+瓣膜手术(35%)。
- 主要疗效终点心脏切开后心力衰竭至出院发生率为6%,主要安全终点复合事件发生率为12%。
- 30天和90天死亡率分别为2%和4%。
- 术后24小时内VISmax<10,拔管时间14.4小时,住院时间13.9天。
临床怎么用
- 对于严重左心室功能不全的高风险心脏手术患者,可考虑在脱离体外循环前启动Impella 5.5经瓣膜左心室卸载。
局限性
- 单臂研究设计,无对照组,结果需进一步随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the safety and feasibility of Impella 5.5-protected cardiac surgery in patients with severe left ventricular dysfunction. METHODS: Impella-Protected Cardiac Surgery Trial is a prospective, multicenter, single-arm study assessing the safety and feasibility of initiating transvalvular left ventricular unloading prior to separation from cardiopulmonary bypass. Eligible patients had a reduced left ventricular ejection fraction with planned elective or urgent conventional cardiac surgery. Patients were supported with the Impella 5.5 for at least 24 hours postoperation. Key exclusion criteria included preoperative inotropic or mechanical circulatory support. A clinical events committee adjudicated end points. RESULTS: One hundred subjects were enrolled at 18 sites in the United States, all of whom successfully received the Impella 5.5. Baseline left ventricular ejection fraction was 25% (interquartile range [IQR], 21.6, 28.9), and Society of Thoracic Surgeons' Predicted Risk of Mortality was 4.1% (IQR, 2.5, 7.1). The index cardiac procedure was primarily isolated coronary artery bypass graft (56%) or coronary artery bypass graft + valve (35%). Post-cardiotomy cardiac failure through hospital discharge, the primary effectiveness end point, occurred in 6% of subjects. The composite of all-cause mortality, stroke, and a new requirement for renal replacement therapy through 90 days postoperation, the primary safety end point, occurred in 12% of subjects. The 30- and 90-day mortality was 2% and 4%, respectively. Subjects had a favorable postoperative trajectory with low perioperative vasoactive inotrope score (VIS) (VISmax <10 within 24 hours postoperation), timely extubation (14.4 hours), and an acceptable hospital length of stay (13.9 days). CONCLUSIONS: Impella 5.5-protected cardiac surgery appears safe and feasible and is a promising device-supported strategy for cardiac surgery patients with severe left ventricular dysfunction.
引用
- Goldstein DJ, Soltesz EG, Batsides G, et al. Preemptive transvalvular mechanical circulatory support is safe and feasible in high-risk cardiac surgery patients: Results of Impella-Protected Cardiac Surgery Trial. J Thorac Cardiovasc Surg. 2026. PMID: 42628913. doi:10.1016/j.jtcvs.2026.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。